Derivatives of rapamycin with improved pharmacokinetics and reduced immunosuppressive effects have been developed (ie, temsirolimus, everolimus, and ridaforolimus) and currently are under clinical investigation.9, 10 This article briefly describes the mTOR pathway and its role in cancer and reviews data from preclinical and clinical studies of mTOR inhibitors, specifically those being investigated in sarcoma. This evidence concerns the gene MTOR and sarcoma.